Peter J H Scott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5508713/publications.pdf

Version: 2024-02-01

172 papers

4,713 citations

35 h-index 60 g-index

249 all docs

249 docs citations

times ranked

249

4570 citing authors

#	Article	IF	CITATIONS
1	A Comprehensive Assessment of ⁶⁸ Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Journal of Nuclear Medicine, 2022, 63, 567-572.	5.0	20
2	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
3	Synthesis of Radiopharmaceuticals via "In-Loop―11C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase. Frontiers in Nuclear Medicine, 2022, 1, .	1.2	9
4	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. Aging Brain, 2022, 2, 100039.	1.3	15
5	No Dopamine Agonist Modulation of Brain [¹⁸ F]FEOBV Binding in Parkinson's Disease. Molecular Pharmaceutics, 2022, 19, 1176-1182.	4.6	1
6	Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging. Nature Protocols, 2022, 17, 980-1003.	12.0	7
7	Radiosynthesis and <i>In Vivo</i> Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors. ACS Chemical Neuroscience, 2022, 13, 1382-1394.	3.5	4
8	Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides. Journal of the American Chemical Society, 2022, 144, 7422-7429.	13.7	11
9	Automated Synthesis of 18F-BCPP-EF {2-tert-Butyl-4-Chloro-5-{6-[2-(2[18F]fluoroethoxy)-Ethoxy]-Pyridin-3-ylmethoxy}-2H-Pyridazin-3-One for Imaging of Mitochondrial Complex 1 in Parkinson's Disease. Frontiers in Chemistry, 2022, 10, 878835.	3.6	1
10	Editorial: Positron Emission Tomography (PET) Imaging of Brain Biochemistry: Beyond High-Affinity Radioligands. Frontiers in Neuroscience, 2022, 16, 907460.	2.8	1
11	Radiosynthesis and initial preclinical evaluation of [11C]AZD1283 as a potential P2Y12R PET radiotracer. Nuclear Medicine and Biology, 2022, 114-115, 143-150.	0.6	3
12	<i>In Silico</i> Approaches for Addressing Challenges in CNS Radiopharmaceutical Design. ACS Chemical Neuroscience, 2022, 13, 1675-1683.	3.5	6
13	Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits. Journal of Neural Transmission, 2022, 129, 1001-1009.	2.8	8
14	Iridiumâ€katalysierte Câ€Hâ€Borylierung von Heteroarenen: Eine Balance zwischen sterischer and elektronischer Regiokontrolle. Angewandte Chemie, 2021, 133, 2830-2856.	2.0	27
15	Iridium atalysed Câ^H Borylation of Heteroarenes: Balancing Steric and Electronic Regiocontrol. Angewandte Chemie - International Edition, 2021, 60, 2796-2821.	13.8	95
16	On the consensus nomenclature rules for radiopharmaceutical chemistry $\hat{a} \in \mathbb{C}$ Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
17	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 13.	3.9	1
18	Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease. Brain Communications, 2021, 3, fcab109.	3.3	21

#	Article	IF	CITATIONS
19	Classics in Neuroimaging: Imaging the Cholinergic System with Positron Emission Tomography. ACS Chemical Neuroscience, 2021, 12, 1472-1479.	3.5	7
20	Sequential Ir/Cu-Mediated Method for the <i>Meta</i> -Selective Câ€"H Radiofluorination of (Hetero)Arenes. Journal of the American Chemical Society, 2021, 143, 6915-6921.	13.7	18
21	Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3. Journal of Fluorine Chemistry, 2021, 245, 109760.	1.7	8
22	Tetramethylammonium Fluoride Alcohol Adducts for S _N Ar Fluorination. Organic Letters, 2021, 23, 4493-4498.	4.6	18
23	A Picture Is Worth a Thousand Words: The Power of Neuroimaging. ACS Chemical Neuroscience, 2021, 12, 2553-2554.	3.5	1
24	Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 125-136.	6.4	11
25	S _N Ar Radiofluorination with In Situ Generated [¹⁸ F]Tetramethylammonium Fluoride. Journal of Organic Chemistry, 2021, 86, 14121-14130.	3.2	9
26	Potential Applications of Artificial Intelligence and Machine Learning in Radiochemistry and Radiochemical Engineering. PET Clinics, 2021, 16, 525-532.	3.0	10
27	An updated synthesis of N 1 $\hat{a} \in \hat{a} \in [11 \text{ C}]$ methyl)naltrindole for positron emission tomography imaging of the delta opioid receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 187-193.	1.0	2
28	Synthesis and Evaluation of a Fluorine-18 Radioligand for Imaging Huntingtin Aggregates by Positron Emission Tomographic Imaging. Frontiers in Neuroscience, 2021, 15, 766176.	2.8	7
29	Evaluation of [¹⁸ F]- <i>N</i> -Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies. ACS Chemical Neuroscience, 2020, 11, 427-435.	3.5	20
30	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. Molecules, 2020, 25, 119.	3.8	8
31	Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions. Molecular Imaging, 2020, 19, 153601212093639.	1.4	3
32	Classics in Neuroimaging: Shedding Light on Opioid Receptors with Positron Emission Tomography Imaging. ACS Chemical Neuroscience, 2020, 11, 2906-2914.	3.5	6
33	Fully Automated Radiosynthesis of [¹¹ C]Guanidines for Cardiac PET Imaging. ACS Medicinal Chemistry Letters, 2020, 11, 2325-2330.	2.8	4
34	Strategies for PET imaging of the receptor for advanced glycation endproducts (RAGE). Journal of Pharmaceutical Analysis, 2020, 10, 452-465.	5. 3	11
35	A spot test for determination of residual TBA levels in ¹⁸ F-radiotracers for human use using Dragendorff reagent. Analytical Methods, 2020, 12, 5004-5009.	2.7	8
36	Improved Synthesis of [¹¹ C]COU and [¹¹ C]PHXY, Evaluation of Neurotoxicity, and Imaging of MAOs in Rodent Heart. ACS Medicinal Chemistry Letters, 2020, 11, 2300-2304.	2.8	2

#	Article	IF	CITATIONS
37	Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 25.	3.9	54
38	Synthesis and Evaluation of ¹¹ C- and ¹⁸ F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents. ACS Medicinal Chemistry Letters, 2020, 11, 1299-1304.	2.8	1
39	Copper-mediated late-stage radiofluorination: five years of impact on preclinical and clinical PET imaging. Clinical and Translational Imaging, 2020, 8, 167-206.	2.1	44
40	Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13.	0.6	7
41	The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. Molecules, 2020, 25, 1360.	3.8	6
42	Classics in Neuroimaging: Development of Positron Emission Tomography Tracers for Imaging the GABAergic Pathway. ACS Chemical Neuroscience, 2020, 11, 2039-2044.	3.5	9
43	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7. Molecules, 2020, 25, 2968.	3.8	5
44	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1576-1585.	4.3	47
45	NHC-Copper Mediated Ligand-Directed Radiofluorination of Aryl Halides. Journal of the American Chemical Society, 2020, 142, 7362-7367.	13.7	33
46	Synthesis of high-molar-activity [18F]6-fluoro-l-DOPA suitable for human use via Cu-mediated fluorination of a BPin precursor. Nature Protocols, 2020, 15, 1742-1759.	12.0	26
47	Synthesis and evaluation of NLRP3-inhibitory sulfonylurea [11C]MCC950 in healthy animals. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127186.	2.2	14
48	Production of radiometals in liquid targets. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 2.	3.9	32
49	Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC). EJNMMI Radiopharmacy and Chemistry, 2020, 5, 24.	3.9	12
50	Synthesis of $[18F]$ - \hat{l}^3 -Fluoro- $\hat{l}\pm,\hat{l}^2$ -unsaturated Esters and Ketones via Vinylogous 18F-Fluorination of $\hat{l}\pm$ -Diazoacetates with $[18F]$ AgF. Synthesis, 2019, 51, 4401-4407.	2.3	10
51	Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase. ACS Chemical Neuroscience, 2019, 10, 3839-3846.	3.5	37
52	Structural Basis for Achieving GSK- $3\hat{l}^2$ Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. Journal of Medicinal Chemistry, 2019, 62, 9600-9617.	6.4	31
53	One-pot synthesis of high molar activity 6-[18F]fluoro-l-DOPA by Cu-mediated fluorination of a BPin precursor. Organic and Biomolecular Chemistry, 2019, 17, 8701-8705.	2.8	37
54	Synthesis of 6-(Fluoromethyl)-19-norcholest-5(10)-en-3-ol, a Fluorinated Analogue of NP-59, using the Mild Fluorinating Reagent, TBAF(Pinacol)2. SynOpen, 2019, 03, 55-58.	1.7	3

#	Article	IF	CITATIONS
55	Evaluating Cholinergic Receptor Expression in Guinea Pig Primary Auditory and Rostral Belt Cortices After Noise Damage Using [³ H]Scopolamine and [¹⁸ F]Flubatine Autoradiography. Molecular Imaging, 2019, 18, 153601211984892.	1.4	0
56	Ring opening of epoxides with [¹⁸ F]FeF species to produce [¹⁸ F]fluorohydrin PET imaging agents. Chemical Communications, 2019, 55, 6361-6364.	4.1	11
57	First-in-Human Brain Imaging of [$<$ sup $>$ 18 $<$ /sup $>$ F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. ACS Chemical Neuroscience, 2019, 10, 2697-2702.	3.5	19
58	Equipment and Instrumentation for Radiopharmaceutical Chemistry., 2019,, 481-499.		2
59	Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. ACS Chemical Neuroscience, 2019, 10, 1867-1871.	3.5	42
60	$\label{eq:cap-18} \text{Ca} \in \text{``H} < \sup 18 < \sup F \text{F. Chemical Communications, } 2019, 55, 2976-2979.$	4.1	20
61	Copperâ€Mediated Aminoquinolineâ€Directed Radiofluorination of Aromatic Câ^'H Bonds with K ¹⁸ F. Angewandte Chemie - International Edition, 2019, 58, 3119-3122.	13.8	40
62	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals, 2019, 12, 7.	3.8	9
63	Copperâ€Mediated Aminoquinolineâ€Directed Radiofluorination of Aromatic Câ^'H Bonds with K 18 F. Angewandte Chemie, 2019, 131, 3151-3154.	2.0	9
64	Development and implementation of ISAR, a new synthesis platform for radiopharmaceutical production. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 24.	3.9	12
65	Automated synthesis of [⁶⁸ Ga]oxine, improved preparation of ⁶⁸ Ga-labeled erythrocytes for blood-pool imaging, and preclinical evaluation in rodents. MedChemComm, 2018, 9, 454-459.	3.4	13
66	Copper(II)-Mediated [$<$ sup $>$ 11 $<$ /sup $>$ C]Cyanation of Arylboronic Acids and Arylstannanes. Organic Letters, 2018, 20, 1530-1533.	4.6	35
67	DARK Classics in Chemical Neuroscience: Cocaine. ACS Chemical Neuroscience, 2018, 9, 2358-2372.	3.5	38
68	Identification of [¹⁸ F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. Journal of Medicinal Chemistry, 2018, 61, 1737-1743.	6.4	36
69	Automated synthesis of PET radiotracers by copperâ€mediated ¹⁸ Fâ€fluorination of organoborons: Importance of the order of addition and competing protodeborylation. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 228-236.	1.0	36
70	Synthesis and Initial In Vivo Evaluation of [11C]AZ683â€"A Novel PET Radiotracer for Colony Stimulating Factor 1 Receptor (CSF1R). Pharmaceuticals, 2018, 11, 136.	3.8	25
71	Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 12.	3.9	10
72	Radiosynthesis of [$<$ sup $>$ 11 $<$ /sup $>$ C]LY2795050 for Preclinical and Clinical PET Imaging Using Cu(II)-Mediated Cyanation. ACS Medicinal Chemistry Letters, 2018, 9, 1274-1279.	2.8	12

#	Article	IF	CITATIONS
73	Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products. Theranostics, 2018, 8, 6352-6354.	10.0	5
74	First-in-Human Studies of [¹⁸ F] Fluorohydroxyphenethylguanidines. Circulation: Cardiovascular Imaging, 2018, 11, e007965.	2.6	23
75	Evaluation of Enzyme Substrate Radiotracers as PET/MRS Hybrid Imaging Agents. ACS Medicinal Chemistry Letters, 2018, 9, 1140-1143.	2.8	3
76	Issues in preclinical radiopharmaceutical research: Significance, relevance and reproducibility. Nuclear Medicine and Biology, 2018, 67, 52-55.	0.6	1
77	Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1. ACS Chemical Neuroscience, 2018, 9, 2767-2773.	3. 5	8
78	Synthesis and pre-clinical evaluation of a potential radiotracer for PET imaging of the dopamine D3 receptor. MedChemComm, 2018, 9, 1315-1322.	3.4	3
79	Gallium-68: methodology and novel radiotracers for positron emission tomography (2012–2017). Pharmaceutical Patent Analyst, 2018, 7, 193-227.	1.1	12
80	Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B. ACS Chemical Neuroscience, 2018, 9, 3024-3027.	3 . 5	15
81	Development of Customized [18F]Fluoride Elution Techniques for the Enhancement of Copper-Mediated Late-Stage Radiofluorination. Scientific Reports, 2017, 7, 233.	3.3	51
82	An updated synthesis of [¹¹ C]carfentanil for positron emission tomography (PET) imaging of the μâ€opioid receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 375-380.	1.0	17
83	Clinical Applications of Radiolabeled Peptides for PET. Seminars in Nuclear Medicine, 2017, 47, 493-523.	4.6	49
84	Preclinical Evaluation of ¹¹ C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1216-1223.	5.0	15
85	Is logP truly dead?. Nuclear Medicine and Biology, 2017, 54, 41-42.	0.6	4
86	Guest Editorial. Seminars in Nuclear Medicine, 2017, 47, 427-428.	4.6	1
87	Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. Seminars in Nuclear Medicine, 2017, 47, 429-453.	4.6	25
88	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Journal of Medicinal Chemistry, 2017, 60, 6897-6910.	6.4	20
89	An updated radiosynthesis of [18F]AV1451 for tau PET imaging. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 7.	3.9	14
90	Cu-Mediated C–H ¹⁸ F-Fluorination of Electron-Rich (Hetero)arenes. Organic Letters, 2017, 19, 3939-3942.	4.6	87

#	Article	IF	Citations
91	High-Yielding Automated Convergent Synthesis of No-Carrier-Added [11C-Carbonyl]-Labeled Amino Acids Using the Strecker Reaction. Synlett, 2017, 28, 371-375.	1.8	8
92	Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation. Journal of Neural Transmission, 2016, 123, 421-424.	2.8	26
93	Synthesis of Diverse ¹¹ C-Labeled PET Radiotracers via Direct Incorporation of [¹¹ C]CO ₂ . Bioconjugate Chemistry, 2016, 27, 1382-1389.	3.6	38
94	Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 366-373.	2.5	23
95	Copper-Mediated Radiofluorination of Arylstannanes with [¹⁸ F]KF. Organic Letters, 2016, 18, 5440-5443.	4.6	151
96	Striatal and <scp>C</scp> ortical βâ€ <scp>A</scp> myloidopathy and <scp>C</scp> ognition in <scp>P</scp> arkinson's <scp>D</scp> isease. Movement Disorders, 2016, 31, 111-117.	3.9	52
97	Radiochemistry, PET Imaging, and the Internet of Chemical Things. ACS Central Science, 2016, 2, 497-505.	11.3	14
98	Fluorine-18 patents (2009–2015). Part 2: new radiochemistry. Pharmaceutical Patent Analyst, 2016, 5, 319-349.	1.1	13
99	Investigation of Proposed Activity of Clarithromycin at GABA _A Receptors Using [¹¹ C]Flumazenil PET. ACS Medicinal Chemistry Letters, 2016, 7, 746-750.	2.8	3
100	Synthesis and Evaluation of [¹⁸ F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts. ACS Chemical Neuroscience, 2016, 7, 391-398.	3.5	32
101	Fluorine-18 patents (2009–2015). Part 1: novel radiotracers. Pharmaceutical Patent Analyst, 2016, 5, 17-47.	1.1	12
102	Moving Metal-Mediated ¹⁸ F-Fluorination from Concept to Clinic. ACS Central Science, 2016, 2, 128-130.	11.3	44
103	Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects. JAMA Neurology, 2015, 72, 194.	9.0	121
104	Synthesis of [¹⁸ F]Arenes via the Copper-Mediated [¹⁸ F]Fluorination of Boronic Acids. Organic Letters, 2015, 17, 5780-5783.	4.6	199
105	Clinical markers for identifying cholinergic deficits in Parkinson's disease. Movement Disorders, 2015, 30, 269-273.	3.9	54
106	Synthesis and evaluation of [$\langle \sup 11 \langle \sup \rangle C$]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid \hat{l}^2 aggregation. MedChemComm, 2015, 6, 1065-1068.	3.4	14
107	Synthesis and Initial <i>in Vivo</i> Studies with [¹¹ C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. ACS Medicinal Chemistry Letters, 2015, 6, 548-552.	2.8	38
108	<i>In Vivo</i> Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity. ACS Chemical Neuroscience, 2015, 6, 1965-1971.	3.5	14

#	Article	IF	CITATIONS
109	Green approaches to late-stage fluorination: radiosyntheses of ¹⁸ F-labelled radiopharmaceuticals in ethanol and water. Chemical Communications, 2015, 51, 14805-14808.	4.1	22
110	Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. Parkinsonism and Related Disorders, 2015, 21, 1227-1231.	2.2	18
111	Targeting Metal-Aβ Aggregates with Bifunctional Radioligand [¹¹ C]L2-b and a Fluorine-18 Analogue [¹⁸ F]FL2-b. ACS Medicinal Chemistry Letters, 2015, 6, 112-116.	2.8	11
112	Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism and Related Disorders, 2014, 20, 1394-1398.	2.2	71
113	Ethanolic carbon-11 chemistry: The introduction of green radiochemistry. Applied Radiation and Isotopes, 2014, 89, 125-129.	1.5	20
114	Extraâ€nigral pathological conditions are common in Parkinson's disease with freezing of gait: An ⟨i⟩in vivo⟨ i⟩ positron emission tomography study. Movement Disorders, 2014, 29, 1118-1124.	3.9	101
115	Late-stage [¹⁸ F]fluorination: new solutions to old problems. Chemical Science, 2014, 5, 4545-4553.	7.4	266
116	In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5- ¹⁸ F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses. Journal of Nuclear Medicine, 2014, 55, 396-404.	5.0	107
117	Copper-Catalyzed [¹⁸ F]Fluorination of (Mesityl)(aryl)iodonium Salts. Organic Letters, 2014, 16, 3224-3227.	4.6	197
118	Synthesis and evaluation of [11C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3 \hat{l}^2 (GSK-3 \hat{l}^2). Nuclear Medicine and Biology, 2014, 41, 507-512.	0.6	27
119	Carbon-11 labeled cathepsin K inhibitors: Syntheses and preliminary in vivo evaluation. Nuclear Medicine and Biology, 2014, 41, 384-389.	0.6	5
120	High Affinity Radiopharmaceuticals Based Upon Lansoprazole for PET Imaging of Aggregated Tau in Alzheimer's Disease and Progressive Supranuclear Palsy: Synthesis, Preclinical Evaluation, and Lead Selection. ACS Chemical Neuroscience, 2014, 5, 718-730.	3.5	77
121	Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination. Current Topics in Medicinal Chemistry, 2014, 14, 875-900.	2.1	121
122	Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain, 2013, 136, 3282-3289.	7.6	140
123	Synthesis of perfluorinated analogs of DOTA and NOTA: bifunctional chelating groups with potential applications in hybrid molecular imaging. Tetrahedron Letters, 2013, 54, 5755-5757.	1.4	4
124	A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate. Applied Radiation and Isotopes, 2013, 78, 26-32.	1.5	27
125	Novel fluorine-18 PET radiotracers based on flumazenil for GABAA imaging in the brain. Nuclear Medicine and Biology, 2013, 40, 901-905.	0.6	15
126	Enhanced radiosyntheses of [11C]raclopride and [11C]DASB using ethanolic loop chemistry. Nuclear Medicine and Biology, 2013, 40, 109-116.	0.6	22

#	Article	IF	CITATIONS
127	(â^')â€{ ¹⁸ F]Flubatine: evaluation in rhesus monkeys and a report of the first fully automated radiosynthesis validated for clinical use. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 595-599.	1.0	22
128	Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology, 2013, 81, 1611-1616.	1.1	185
129	Synthesis of [18F]-Fluorodeoxyglucose ([18F]FDG)., 2012,, 1-13.		5
130	Synthesis of [18F]Fluoroethyltyrosine (18F-FET)., 2012,, 103-110.		0
131	Synthesis of (+)-α-[11C]Dihydrotetrabenazine ([11C]DTBZ). , 2012, , 213-219.		1
132	Synthesis of [11C]Carfentanil ([11C]CFN)., 2012,, 257-264.		1
133	Evaluation of [¹¹ C] <i>N</i> -Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. ACS Medicinal Chemistry Letters, 2012, 3, 936-941.	2.8	52
134	Fully automated radiosynthesis of [11C]PBR28, a radiopharmaceutical for the translocator protein (TSPO) 18kDa, using a GE TRACERlab FXC-Pro. Applied Radiation and Isotopes, 2012, 70, 1779-1783.	1.5	9
135	Synthesis of [18F]Fluorocholine ([18F]FCH)., 2012,, 61-68.		0
136	Synthesis of [18F]Fluoroazomycin Arabinoside ([18F]FAZA)., 2012,, 31-39.		0
137	Synthesis of [13N]Ammonia ([13N]NH3). , 2012, , 313-320.		0
138	Novel Strategies for Fluorineâ€18 Radiochemistry. Angewandte Chemie - International Edition, 2012, 51, 1106-1109.	13.8	96
139	Current imaging strategies in rheumatoid arthritis. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 174-220.	1.0	33
140	Highlighting the versatility of the tracerlab synthesis modules. Part 1: fully automated production of $[\langle sup \rangle 18 \langle sup \rangle F]$ labelled radiopharmaceuticals using a Tracerlab FX $\langle sub \rangle FN \langle sub \rangle$. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 292-307.	1.0	76
141	Highlighting the versatility of the Tracerlab synthesis modules. Part 2: fully automated production of [¹¹ C]â€labeled radiopharmaceuticals using a Tracerlab FX _{Câ€Pro} . Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 819-838.	1.0	53
142	Automated production of $[11C]$ acetate and $[11C]$ palmitate using a modified GE Tracerlab FXC-Pro. Applied Radiation and Isotopes, 2011, 69, 691-698.	1.5	22
143	Fully automated preparation of [11C]choline and [18F]fluoromethylcholine using TracerLab synthesis modules and facilitated quality control using analytical HPLC. Applied Radiation and Isotopes, 2011, 69, 403-409.	1.5	38
144	Fully automated, high yielding production of <i>N</i> â€succinimidyl 4â€[¹⁸ F]fluorobenzoate ([¹⁸ F]SFB), and its use in microwaveâ€enhanced radiochemical coupling reactions. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 586-591.	1.0	27

#	Article	IF	CITATIONS
145	A novel one-pot palladium-mediated synthesis of N- $[(2-hydroxyphenyl)]$ methyl]-N- $(4-phenoxy-3-pyridinyl)$ acetamide, the precursor to $[11C]$ PBR28, a PET biomarker for the peripheral benzodiazepine receptor. Tetrahedron Letters, 2010, 51, 3353-3355.	1.4	3
146	An automated method for preparation of [18F]sodium fluoride for injection, USP to address the technetium-99m isotope shortage. Applied Radiation and Isotopes, 2010, 68, 117-119.	1.5	24
147	Besilesomab for imaging inflammation and infection in peripheral bone in adults with suspected osteomyelitis. Reports in Medical Imaging, 2010, , 17.	0.8	1
148	Methods for the Incorporation of Carbonâ€11 To Generate Radiopharmaceuticals for PET Imaging. Angewandte Chemie - International Edition, 2009, 48, 6001-6004.	13.8	72
149	Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography. Applied Radiation and Isotopes, 2009, 67, 88-94.	1.5	58
150	Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use. Applied Radiation and Isotopes, 2007, 65, 1359-1362.	1.5	30
151	Diversity Linker Units for Solidâ€Phase Organic Synthesis. European Journal of Organic Chemistry, 2006, 2006, 2251-2268.	2.4	42
152	A General Method for the Preparation of Perfluoroalkanesulfonyl Chlorides ChemInform, 2005, 36, no.	0.0	0
153	A general method for the preparation of perfluoroalkanesulfonyl chlorides. Journal of Fluorine Chemistry, 2005, 126, 1196-1201.	1.7	6
154	[11C]Carbon Dioxide: Starting Point for Labeling PET Radiopharmaceuticals., 0,,.		4
155	Synthesis of 4-(2′-Methoxyphenyl)-1-[2′-(N-2″Pyridinyl)-p-[18F]Fluorobenzamido]Ethylpiperazine [18F]M, 0, , 87-94.	IPPF.	2
156	Synthesis of 6-[18F]Fluorodopamine (6-[18F]FDA)., 0,, 125-138.		5
157	Synthesis of [11C]-meta-Hydroxyephedrine ([11C]MHED)., 0, , 191-198.		2
158	Synthesis of L-[methyl-11C] Methionine ([11C] MET)., 0,, 199-212.		5
159	Synthesis of [68Ga]Gallium Dota-(Tyr3)-Octreotide Acetate ([68Ga]-Dotatoc)., 0,, 321-334.		3
160	Synthesis of [18F]FPPRGD2., 0,, 51-60.		2
161	Linker Selection Tables. , 0, , 589-655.		0
162	Synthesis of [carbonyl-11C]Way-100635., 0,, 265-273.		1

#	Article	IF	CITATIONS
163	Synthesis of [18F]Fluoromisonidazole (1-(2-Hydroxy-3-[18F]Fluoropropyl)-2-Nitroimidazole, [18F]FMISO)., 0,, 41-49.		1
164	Synthesis of 2-(4-N-[11C]Methylaminophenyl)-6-Hydroxybenzothiazole ([11C]6-OH-BTA-1; [11C]PIB)., 0, , 177-189.		0
165	Clinical Manufacturing of [18F]-16-α-Fluoroestradiol ([18F]FES)., 0,, 69-80.		1
166	Synthesis of 3-Amino-4-[2-(N-Methyl-N-[11C]Methyl-Amino-Methyl)Phenylsulfanyl]-Benzonitrile ([11C]DASB). , 0, , 285-296.		0
167	Synthesis of [18F]-Substance-P Antagonist-Receptor Quantifier ([18F]SPA-RQ)., 0,, 155-166.		O
168	Synthesis of [11C]Acetate., 0,, 297-303.		1
169	Synthesis of Sodium [18F]Fluoride (Na[18F]F)., 0,, 15-19.		O
170	Appendix 1: Supplier Information. , 0, , 335-338.		0
171	Synthesis of [11C]Hexadecanoic Acid ([11C]Palmitic Acid)., 0,, 233-243.		O
172	Unnatural amino acids offer new hope for accurate bacterial infection PET imaging in prosthetic joint infection. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0